Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.54. Tessa Romero – JPMorgan: Yigal ...

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

FYB203, a biosimilar to aflibercept, received UK MHRA approval for multiple retinal conditions and will be marketed as ...

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is ...

Adverum Biotechnologies (ADVM) announced the initiation of the ARTEMIS Phase 3 study. This pivotal trial is designed to evaluate the efficacy ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...